SCHEMBL7548637

SCHEMBL7548637

CC(C)(N)Cc1cc[c]cc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.60
TAAR1 Q96RJ0 1/20 0.60
HTR2A P28223 1/20 0.56
SLC6A4 P31645 1/20 0.56
HRH1 P35367 1/20 0.56
HTR2B P41595 1/20 0.56
CHRNA4 P43681 1/20 0.56
SLC6A3 Q01959 1/20 0.56
BLM P54132 1/20 0.34
ESR1 P03372 2/20 0.33
GHSR Q92847 8/20 0.32
LMNA P02545 1/20 0.31
CYP2D6 P10635 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30
HIF1A Q16665 1/20 0.30
ESR2 Q92731 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23005 0.80 ESR1 (0.52) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL28729624 0.78 SLC6A2 (0.95) SLC6A2TAAR1HTR2ASLC6A4HRH1
SCHEMBL28040853 0.78 ESR1 (0.50) SLC6A2TAAR1HTR2ASLC6A4HRH1
SCHEMBL1417168 0.76 ESR1 (0.38) SLC6A2TAAR1HTR2ASLC6A4HRH1
SCHEMBL1031401 0.76 ESR1 (0.38) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL25214698 0.76 SLC6A2 (0.91) SLC6A2TAAR1HTR2ASLC6A4HRH1
SCHEMBL28040364 0.76 ESR1 (0.48) SLC6A2TAAR1HTR2ASLC6A4HRH1
SCHEMBL228926 0.75 SLC6A2 (0.67) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL10392295 0.75 SLC6A2 (1.00) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL26615 0.75 SLC6A2 (1.00) SLC6A2TAAR1HTR2ASLC6A4HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110023312-A The Compounds and methods for for preventing malarial parasite from propagating 由卫生与公众服务部部长代表的美利坚合众国 2019-07-16 CN claimed
CN-1060487-C Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same PROCTER & GAMBLE (US) 2001-01-10 CN claimed
CN-1133603-A Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same PROCTER & GAMBLE (US) 1996-10-16 CN claimed
CN-110023312-A The Compounds and methods for for preventing malarial parasite from propagating 由卫生与公众服务部部长代表的美利坚合众国 2019-07-16 CN disclosed
US-20020082254-A1 Compounds for treating disorders where a decreased level of plasma FFA is desired NOVO NORDISK A/S (DK) 2002-06-27 US disclosed
WO-2001087843-A1 COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED NOVO NORDISK A/S (DK) 2001-11-22 WO disclosed
EP-0078152-B1 SALTS OF SULFODEHYDROABIETIC ACID AND TREATMENT OF GASTRO-INTESTINAL DISEASES Tanabe Seiyaku Co., Ltd. (JP) 1986-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082254-A1 Compounds for treating disorders where a decreased level of plasma FFA is desired FABP1, FFAR2, FFAR1 SLC6A2 1103/4885TAAR1 1819/4885HTR2A 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.